New hope for bladder cancer patients who Can't take chemo
NCT ID NCT03601455
First seen May 12, 2026 · Last updated Jun 23, 2026 · Updated 2 times
Summary
This study tests whether combining radiation therapy with immunotherapy drugs (durvalumab with or without tremelimumab) can help people with advanced bladder cancer who cannot or will not have chemotherapy. The trial includes 13 participants with cancer that has spread or cannot be removed by surgery. Researchers are checking for side effects and how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV BLADDER CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Durvalumab (Imfinzi) and tremelimumab, both immunotherapy drugs, plus external beam radiation therapy
What this could lead to
If it works, this could offer a chemotherapy-free treatment option for advanced bladder cancer, potentially controlling the disease for longer.
What could go wrong
This is a small, early-phase trial (13 participants) focused on safety and progression-free survival. The combination may not work better than standard care, and side effects from immunotherapy and radiation can be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.